Modeling timelines for translational science in cancer; the impact of technological maturation

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  McNamee, Laura M ^a   Ledley, Fred D ^a  

^a BENTLEY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; PLATINUM COMPLEX; PREDNISONE; PROTEASOME INHIBITOR; PROTEIN SYNTHESIS INHIBITOR; THALIDOMIDE DERIVATIVE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RESEARCH; CANCER THERAPY; HUMAN; MEDICAL LITERATURE; MEDICAL TECHNOLOGY; PRODUCT DEVELOPMENT; TRANSLATIONAL RESEARCH; BIOTECHNOLOGY; MASS COMMUNICATION; NEOPLASMS; THEORETICAL MODEL;

ANTINEOPLASTIC AGENTS; BIOTECHNOLOGY; DIFFUSION OF INNOVATION; HUMANS; MODELS, THEORETICAL; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85016425647     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0174538     Document Type: Article

References (80)

1. Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell. 2011; 145(1):19-24. https://doi.org/10.1016/j.cell.2011.03.026 PMID: 21458664
2. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science. 2000; 287(5460):1969-73. PMID: 10720316
3. Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nature Reviews Cancer. 2005; 5 (1):65-72. https://doi.org/10.1038/nrc1529 PMID: 15630416
4. Bailar JC, Gornik HL. Cancer undefeated. New England Journal of Medicine. 1997; 336(22):1569-74. https://doi.org/10.1056/NEJM199705293362206 PMID: 9164814
5. Varmus H. The new era in cancer research. Science. 2006; 312(5777):1162-5. https://doi.org/10.1126/science.1126758 PMID: 16728627
6. Nathan DG. The cancer treatment revolution. Transactions of the American Clinical and Climatological Association. 2007; 118:317. PMID: 18528513
7. Vogelstein B, Kinzler KW. Winning the war: science parkour. Sci Transl Med. 2012; 4:127.
8. Alberts B, Kirschner MW, Tilghman S, Varmus H. Rescuing US biomedical research from its systemic flaws. Proceedings of the National Academy of Sciences. 2014; 111(16):5773-7.
9. Gillum LA, Gouveia C, Dorsey ER, Pletcher M, Mathers CD, McCulloch CE, et al. NIH disease funding levels and burden of disease. PLoS One. 2011; 6(2):e16837. https://doi.org/10.1371/journal.pone. 0016837 PMID: 21383981
10. Sansone S-A, Rocca-Serra P, Field D, Maguire E, Taylor C, Hofmann O, et al. Toward interoperable bioscience data. Nature genetics. 2012; 44(2):121-6. https://doi.org/10.1038/ng.1054 PMID: 22281772
11. Varmus H, Harlow E. Science funding: provocative questions in cancer research. Nature. 2012; 481 (7382):436-7. https://doi.org/10.1038/481436a PMID: 22281578
12. Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature. 2012; 483(7391):531-3. https://doi.org/10.1038/483531a PMID: 22460880
13. Collins FS. Reengineering translational science: the time is right. Science translational medicine. 2011; 3(90):90cm17-90cm17. https://doi.org/10.1126/scitranslmed.3002747 PMID: 21734173
14. Hutton J. Transforming Translation-Harnessing Discovery for Patient and Public Benefit. Report of the Translational Research Working Group of the National Cancer Advisory Board. 2007.
15. Faguet GB. The war on cancer: Springer; 2005.
16. Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nature Reviews Drug Discovery. 2007; 6(2):115-20. https://doi.org/10.1038/nrd2155 PMID: 17159925
17. Sorger PK, Allerheiligen SR, Abernethy DR, Altman RB, Brouwer KL, Califano A, et al., editors. Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. An NIH white paper by the QSP workshop group; 2011: NIH Bethesda.
18. Balconi M, Brusoni S, Orsenigo L. In defence of the linear model: An essay. Research Policy. 2010; 39 (1):1-13.
19. Godin B. The Linear model of innovation the historical construction of an analytical framework. Science, Technology & Human Values. 2006; 31(6):639-67.
20. Edgerton D. The Linear Model.
21. Stokes DE. Pasteur's quadrant: Basic science and technological innovation: Brookings Institution Press; 2011.
22. Narayanamurti V. Cycles of Invention and Discovery: Harvard University Press; 2016.
23. Bush V. The Endless Frontier, Report to the President on a Program for Postwar Scientific Research. DTIC Document, 1945.
24. Sampat BN, Mowery DC, editors. Universities in national innovation systems2004: Georgia Institute of Technology.
25. Mankins JC. Technology readiness assessments: A retrospective. Acta Astronautica. 2009; 65 (9):1216-23.
26. Mankins JC. Technology readiness levels. White Paper, April. 1995;6.
27. Office USGA. Technology Readiness Assessment Guide. August 2016.
28. Gannon F. The steps from translatable to translational research. EMBO reports. 2014; 15(11):1107-8. https://doi.org/10.15252/embr.201439587 PMID: 25296643
29. Woolf SH. The meaning of translational research and why it matters. Jama. 2008; 299(2):211-3. https://doi.org/10.1001/jama.2007.26 PMID: 18182604
30. Foster RN. Innovation: The attacker's advantage: Summit Books; 1988.
31. Christensen CM. The innovator's dilemma: the revolutionary book that will change the way you do business: Harper Business Essentials New York, NY; 2003.
32. Christensen CM. Exploring the limits of the technology S-curve. Part I: component technologies. Production and Operations Management. 1992; 1(4):334-57.
33. Christensen CM. Exploring the limits of the technology S-curve. Part II: Architectural technologies. Production and Operations Management. 1992; 1(4):358-66.
34. Foster RN. Innovation: The attacker's advantage: Summit Books New York; 1986.
35. Christensen C. The innovator's dilemma: when new technologies cause great firms to fail: Harvard Business Review Press; 2013.
36. Louie G. Persistent forecasting of disruptive technologies. Washington, DC: The National Academies Press; 2009.
37. Martino JP. A review of selected recent advances in technological forecasting. Technological Forecasting and Social Change. 2003; 70(8):719-33.
38. Christensen CM, Rosenbloom RS. Explaining the attacker's advantage: Technological paradigms, organizational dynamics, and the value network. Research Policy. 1995; 24(2):233-57.
39. Petrick IJ, Echols AE. Technology roadmapping in review: A tool for making sustainable new product development decisions. Technological Forecasting and Social Change. 2004; 71(1):81-100.
40. Cockburn IM, Henderson RM. Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery. The Journal of Industrial Economics. 1998; 46(2):157-82.
41. Toole AA. The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry. Research Policy. 2012; 41(1):1-12.
42. Austin DH, editor Research and development in the pharmaceutical industry2006: Congress of the United States, Congressional Budget Office.
43. Lichtenberg FR. The impact of biomedical knowledge accumulation on mortality: a bibliometric analysis of cancer data. National Bureau of Economic Research, 2013.
44. Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. Journal of the Royal Society of Medicine. 2011; 104(12):510-20. https://doi.org/10.1258/jrsm.2011.110180 PMID: 22179294
45. McNamee LM, Ledley FD. Patterns of technological innovation in biotech. Nat Biotechnol. 2012; 30 (10):937-43. Epub 2012/10/12. https://doi.org/10.1038/nbt.2389 PMID: 23051809
46. Pisano GP. Science business: The promise, the reality, and the future of biotech: Harvard Business Press; 2006.
47. Jantsch E. Technological forecasting in perspective: OCDE; 1967.
48. Daim TU, Rueda G, Martin H, Gerdsri P. Forecasting emerging technologies: Use of bibliometrics and patent analysis. Technological Forecasting and Social Change. 2006; 73(8):981-1012.
49. Ledley F, McNamee L, Uzdil V, Morgan I. Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies. Gene therapy. 2013.
50. Young P. Technological growth curves: a competition of forecasting models. Technological forecasting and social change. 1993; 44(4):375-89.
51. Meade N, Islam T. Technological forecasting-Model selection, model stability, and combining models. Management Science. 1998; 44(8):1115-30.
52. Nagy B, Farmer JD, Bui QM, Trancik JE. Statistical basis for predicting technological progress. PloS one. 2013; 8(2):e52669. https://doi.org/10.1371/journal.pone.0052669 PMID: 23468837
53. Meade N, Islam T. Forecasting with growth curves: An empirical comparison. International journal of forecasting. 1995; 11(2):199-215.
54. Drews J. Drug discovery: a historical perspective. Science. 2000; 287(5460):1960-4. PMID: 10720314
55. Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug discovery today. 2008; 13(1):30-7.
56. Swinney DC, Anthony J. How were new medicines discovered? Nature reviews Drug discovery. 2011; 10(7):507-19. https://doi.org/10.1038/nrd3480 PMID: 21701501
57. Agarwal P, Searls DB. Can literature analysis identify innovation drivers in drug discovery? Nat Rev Drug Discov. 2009; 8(11):865-78. Epub 2009/10/31. https://doi.org/10.1038/nrd2973 PMID: 19876041
58. Garfield E, Melino G. The growth of the cell death field: an analysis from the ISI-Science citation index. Cell Death Differ. 1997; 4(5):352-61. Epub 1997/07/01. https://doi.org/10.1038/sj.cdd.4400261 PMID: 16465253
59. Marshall A. Trends in biotech literature 2008. Nature Biotechnology. 2009; 27(9):789.
60. Taroncher-Oldenburg G, Marshall A. Trends in biotech literature 2007. Nat Biotechnol. 2008; 26 (10):1062. Epub 2008/10/11. https://doi.org/10.1038/nbt1008-1062 PMID: 18846063
61. Taroncher-Oldenburg G, Marshall A. Trends in biotech literature 2006. Nat Biotechnol. 2007; 25(9):961. Epub 2007/09/12. https://doi.org/10.1038/nbt0907-961 PMID: 17846614
62. Firat AK, Woon WL, Madnick S. Technological forecasting-A review. Composite Information Systems Laboratory (CISL), Massachusetts Institute of Technology. 2008.
63. Beierlein JM, McNamee LM, Walsh MJ, Ledley FD. Patterns of innovation in Alzheimer's disease drug development: a strategic assessment based on technological maturity. Clinical Therapeutics. 2015; 37 (8):1643-51. e3. https://doi.org/10.1016/j.clinthera.2015.07.003 PMID: 26243074
64. Kim W, Aronson AR, Wilbur WJ, editors. Automatic MeSH term assignment and quality assessment. Proceedings of the AMIA Symposium; 2001: American Medical Informatics Association.
65. Fisher JC, Pry RH. A simple substitution model of technological change. Technological forecasting and social change. 1972; 3:75-88.
66. Schully S, Benedicto C, Gillanders E, Wang S, Khoury M. Translational research in cancer genetics: the road less traveled. Public Health Genomics. 2009; 14(1):1-8. https://doi.org/10.1159/000272897 PMID: 20051673
67. Khoury MJ, Gwinn M, Ioannidis JP. The emergence of translational epidemiology: from scientific discovery to population health impact. American journal of epidemiology. 2010; 172(5):517-24. https://doi.org/10.1093/aje/kwq211 PMID: 20688899
68. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genetics in Medicine. 2007; 9(10):665-74.
69. McGeary M, Burstein M. Sources of cancer research funding in the United States. Prepared for the National Cancer Policy Board, Institute of Medicine. 1999.
70. Martell RE, Sermer D, Getz K, Kaitin KI. Oncology drug development and approval of systemic anticancer therapy by the US Food and Drug Administration. The oncologist. 2013; 18(1):104-11. https://doi.org/10.1634/theoncologist.2012-0235 PMID: 23263289
71. Swinney D. Phenotypic vs. target-based drug discovery for first-in-class medicines. Clinical Pharmacology & Therapeutics. 2013; 93(4):299-301.
72. Nelson RR, Buterbaugh K, Perl M, Gelijns A. How medical know-how progresses. Research policy. 2011; 40(10):1339-44.
73. Brown D. Unfinished business: target-based drug discovery. Drug Discovery Today. 2007; 12 (23):1007-12.
74. Eder J, Sedrani R, Wiesmann C. The discovery of first-in-class drugs: origins and evolution. Nature Reviews Drug Discovery. 2014; 13(8):577-87. https://doi.org/10.1038/nrd4336 PMID: 25033734
75. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews. 2012; 64:4-17.
76. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014; 13 (6):419-31. https://doi.org/10.1038/nrd4309 PMID: 24833294
77. McNamee L, Ledley F. Translational Science by Public Biotechnology Companies in the IPO "Class of 2000": The Impact of Technological Maturity. PloS one. 2013; 8(12):e82195. https://doi.org/10.1371/journal.pone.0082195 PMID: 24358154
78. Service CR. Senate Medical Innovation Bills: Overview and Comparison with the 21st Century Cures Act (H.R. 6). May 17, 2016.
79. Collins F. February 4, 2014. Available from: https://directorsblog.nih.gov/2014/02/04/introducing-ampthe-accelerating-medicines-partnership/.
80. Phaal R, Farrukh C, Probert D. Technology Roadmapping: linking technology resources to business objectives. Centre for Technology Management, University of Cambridge. 2001:1-18.